Briacell Therapeutics Corp (BCT : TSX)
Common Stock
$4.51
CAD
-0.05 (-1.10%)
Last updated: 2026-06-02
BCT
Briacell Therapeutics Corp
WealthAwesomePerformance
1 Day
-1.10%
1 Week
-4.65%
1 Month
-20.46%
YTD
-54.07%
Key Statistics
Market Cap
$33.42M
52W High
$49.00
52W Low
$4.13
P/E Ratio
-
50 Day MA
$5.51
200 Day MA
$9.70
Beta
1.63
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/2/2026 | $4.51 | $4.68 | $4.47 | $4.51 | $4.51 | 5,579 |
| 6/1/2026 | $4.69 | $4.69 | $4.40 | $4.56 | $4.56 | 21,537 |
| 5/29/2026 | $5.08 | $5.08 | $4.77 | $5.03 | $5.03 | 5,230 |
| 5/28/2026 | $4.86 | $5.07 | $4.78 | $4.99 | $4.99 | 11,331 |
| 5/27/2026 | $4.72 | $5.05 | $4.72 | $5.05 | $5.05 | 6,457 |
| 5/26/2026 | $4.81 | $4.84 | $4.67 | $4.73 | $4.73 | 6,335 |
| 5/25/2026 | $5.09 | $5.09 | $4.81 | $4.87 | $4.87 | 3,864 |
| 5/22/2026 | $4.99 | $4.99 | $4.68 | $4.79 | $4.79 | 20,879 |
| 5/21/2026 | $5.23 | $5.33 | $5.04 | $5.05 | $5.05 | 8,117 |
| 5/20/2026 | $4.93 | $5.41 | $4.93 | $5.23 | $5.23 | 27,040 |
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 343.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$20.00
+343.5% Upside
Current Price
C$4.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
113.1%
Annualized
90-Day Vol
87.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.77
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$4.25 | C$2.88 โ C$6.28 |
| 60 trading days | C$4.00 | C$2.31 โ C$6.95 |
| 90 trading days | C$3.77 | C$1.92 โ C$7.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-30.63M
- Profit Margin
- 0.00%
- ROE (TTM)
- -179.21%
- EPS (Diluted)
- -19.91
- Book Value
- 5.88
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
๐ Recent Splits
1-for-10
Aug 25, 2025
1-for-15
Jan 29, 2025
1009-for-1000
Sep 5, 2023
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About BCT
Articles Featuring BCT.TO
Latest articles and analysis covering BCT.TO
![10 Best Canadian Biotech Stocks ([currentmonthyear])](https://lhajohzwizrsjmumhpjg.supabase.co/storage/v1/object/public/wealth-awesome/site-media/best-canadian-biotech-stocks_8-1.jpg)